In this episode, listen as Karen H. Costenbader, MD, MPH, and Brad H. Rovin, MD, answer key questions about identifying patients at high risk for lupus nephritis, whether an elevated serum creatinine always signals lupus nephritis, the safety of newer therapies for lupus in women who are pregnant or breastfeeding, and the possibility of using SGLT2 inhibitors in patients with lupus nephritis.Presenters: Karen H. Costenbader, MD, MPHProfessor of MedicineDepartment of MedicineHarvard Medical SchoolDirector, Lupus ProgramDivision of Rheumatology, Inflammation and ImmunityBrigham and Women’s HospitalBoston, MassachusettsBrad H. Rovin, MDProfessor and Director, Division of NephrologyThe Lee A. Hebert Professor of NephrologyMedical Director, The Ohio State Center for Clinical Research ManagementThe Ohio State University Wexner Medical CenterColumbus, OhioReview the downloadable slidesets at: https://bit.ly/3mlHOlaLink to full program:https://bit.ly/3aC2NNL

In this episode, listen as Karen H. Costenbader, MD, MPH, and Brad H. Rovin, MD, answer key questions about identifying patients at high risk for lupus nephritis, whether an elevated serum creatinine always signals lupus nephritis, the safety of newer therapies for lupus in women who are pregnant or breastfeeding, and the possibility of using SGLT2 inhibitors in patients with lupus nephritis.Presenters: Karen H. Costenbader, MD, MPH Professor of Medicine Department of Medicine Harvard Medical School Director, Lupus Program Division of Rheumatology, Inflammation and Immunity Brigham and Women’s Hospital Boston, MassachusettsBrad H. Rovin, MD Professor and Director, Division of Nephrology The Lee A. Hebert Professor of Nephrology Medical Director, The Ohio State Center for Clinical Research Management The Ohio State University Wexner Medical Center Columbus, OhioReview the downloadable slidesets at:  <a href="https://bit.ly/3mlHOla" rel="nofollow" target="_blank">https://bit.ly/3mlHOla</a>Link to full program: <a href="https://bit.ly/3aC2NNL" rel="nofollow" target="_blank">https://bit.ly/3aC2NNL</a>

Key Points in the Management of Lupus and Lupus Nephritis

In this episode, David S. Kountz, MD, discusses with Keith C. Ferdinand MD, FACC, FAHA, a patient case in which health disparities affected NVAF care and provides patient, provider, and health-system level strategies to address these disparities to improve NVAF-related cardiovascular outcomes.PresentersKeith C. Ferdinand, MD, FACC, FAHAProfessor of Medicine Tulane Heart and Vascular InstituteTulane University School of MedicineNew Orleans, LouisianaDavid S. Kountz, MDProfessor of MedicineDepartment of MedicineHackensack Meridian School of MedicineNutley, New JerseyLink to full program:https://bit.ly/3MbIfZI

In this episode, David S. Kountz, MD, discusses with Keith C. Ferdinand MD, FACC, FAHA, a patient case in which health disparities affected NVAF care and provides patient, provider, and health-system level strategies to address these disparities to improve NVAF-related cardiovascular outcomes.PresentersKeith C. Ferdinand, MD, FACC, FAHA Professor of Medicine  Tulane Heart and Vascular Institute Tulane University School of Medicine New Orleans, LouisianaDavid S. Kountz, MD Professor of Medicine Department of Medicine Hackensack Meridian School of Medicine Nutley, New JerseyLink to full program: <a href="https://bit.ly/3MbIfZI" rel="nofollow" target="_blank">https://bit.ly/3MbIfZI</a>

Interview with the Experts: Strategies to Overcome SDOH in NVAF Part 2

In this episode, Keith C. Ferdinand MD, FACC, FAHA, discusses with David S. Kountz, MD, a patient case in which health disparities affected NVAF care and provides strategies to address low health literacy and patient access to direct-acting oral anticoagulant to improve NVAF-related cardiovascular outcomes.PresentersKeith C. Ferdinand, MD, FACC, FAHA Professor of Medicine Tulane Heart and Vascular InstituteTulane University School of MedicineNew Orleans, LouisianaDavid S. Kountz, MDProfessor of MedicineDepartment of MedicineHackensack Meridian School of MedicineNutley, New JerseyLink to full program: https://bit.ly/3MbIfZI

In this episode, Keith C. Ferdinand MD, FACC, FAHA, discusses with David S. Kountz, MD, a patient case in which health disparities affected NVAF care and provides strategies to address low health literacy and patient access to direct-acting oral anticoagulant to improve NVAF-related cardiovascular outcomes.PresentersKeith C. Ferdinand, MD, FACC, FAHA  Professor of Medicine  Tulane Heart and Vascular Institute Tulane University School of Medicine New Orleans, LouisianaDavid S. Kountz, MD Professor of Medicine Department of Medicine Hackensack Meridian School of Medicine Nutley, New JerseyLink to full program:  <a href="https://bit.ly/3MbIfZI" rel="nofollow" target="_blank">https://bit.ly/3MbIfZI</a>

Interview With the Experts: Strategies to Overcome SDOH in NVAF Part 1

In this episode, Karen H. Costenbader, MD, MPH, and Brad H. Rovin, MD, discuss health disparities in systemic lupus erythematosus and lupus nephritis. Topics include: Disproportionate prevalence among marginalized groups in the United StatesLupus-related social determinants of healthChallenges with medication adherenceStrategies to reduce these disparitiesPresenters:Karen H. Costenbader, MD, MPHProfessor of MedicineDepartment of MedicineHarvard Medical SchoolDirector, Lupus ProgramDivision of Rheumatology, Inflammation and ImmunityBrigham and Women’s HospitalBoston, MassachusettsBrad H. Rovin, MDProfessor and Director, Division of NephrologyThe Lee A. Hebert Professor of NephrologyMedical Director, The Ohio State Center for Clinical Research ManagementThe Ohio State University Wexner Medical CenterColumbus, OhioThis episode is part of a larger program titled, “Lupus and Lupus Nephritis: Improving Outcomes and Reducing Disparities.” To access the full program, follow this link: https://bit.ly/3PWAzNU

In this episode, Karen H. Costenbader, MD, MPH, and Brad H. Rovin, MD, discuss health disparities in systemic lupus erythematosus and lupus nephritis. Topics include: <ul><li>Disproportionate prevalence among marginalized groups in the United States</li><li>Lupus-related social determinants of health</li><li>Challenges with medication adherence</li><li>Strategies to reduce these disparities</li></ul>Presenters:Karen H. Costenbader, MD, MPH Professor of Medicine Department of Medicine Harvard Medical School Director, Lupus Program Division of Rheumatology, Inflammation and Immunity Brigham and Women’s Hospital Boston, MassachusettsBrad H. Rovin, MD Professor and Director, Division of Nephrology The Lee A. Hebert Professor of Nephrology Medical Director, The Ohio State Center for Clinical Research Management The Ohio State University Wexner Medical Center Columbus, OhioThis episode is part of a larger program titled, “Lupus and Lupus Nephritis: Improving Outcomes and Reducing Disparities.” To access the full program, follow this link:  <a href="https://bit.ly/3PWAzNU" rel="nofollow" target="_blank">https://bit.ly/3PWAzNU</a>

Reducing Disparities in Lupus and Lupus Nephritis Care

This podcast is the first in a series of 3 featuring an multidisciplinary panel of expert faculty addressing the impact of social determinants of health on NVAF and CV-related outcomes and strategies to overcome these disparities. In this episode, David S. Kountz, MD, provides a detailed explanation of the atrial fibrillation paradox and data on the impacts of SDOH on NVAF CV-related outcomes.Review the downloadable slideset and the full program at: https://bit.ly/3yYXP8e

This podcast is the first in a series of 3 featuring an multidisciplinary panel of expert faculty addressing the impact of social determinants of health on NVAF and CV-related outcomes and strategies to overcome these disparities. In this episode, David S. Kountz, MD, provides a detailed explanation of the atrial fibrillation paradox and data on the impacts of SDOH on NVAF CV-related outcomes.Review the downloadable slideset and the full program at:  <a href="https://bit.ly/3yYXP8e" rel="nofollow" target="_blank">https://bit.ly/3yYXP8e</a>

Overview of SDOH in NVAF and CV-Related Outcomes

This podcast is the third in a series of 3 featuring an expert multidisciplinary panel of faculty addressing the impact of social determinants of health on NVAF and CV-related outcomes and strategies to overcome these disparities. In this episode, Keith C. Ferdinand, MD, FACC, FAHA, details the effects of SDOH on anticoagulation prescribing in NVAF and provides an overview of areas for future study.Review the downloadable slideset and the full program at:https://bit.ly/3yYXP8e

This podcast is the third in a series of 3 featuring an expert multidisciplinary panel of faculty addressing the impact of social determinants of health on NVAF and CV-related outcomes and strategies to overcome these disparities. In this episode, Keith C. Ferdinand, MD, FACC, FAHA, details the effects of SDOH on anticoagulation prescribing in NVAF and provides an overview of areas for future study.Review the downloadable slideset and the full program at: <a href="https://bit.ly/3yYXP8e" rel="nofollow" target="_blank">https://bit.ly/3yYXP8e</a>

NVAF Management and Future Directions

This podcast is the second in a series of 3 featuring an expert multidisciplinary panel of faculty addressing the impact of social determinants of health on NVAF and CV-related outcomes and strategies to overcome these disparities. In this episode, Laura Ross PA-C, CLS, dives deeper into the impacts of SODH on NVAF care and provides strategies to address to improve patient care and clinical outcomes in NVAF.Review the downloadable slideset and the full program at:   https://bit.ly/3yYXP8e

This podcast is the second in a series of 3 featuring an expert multidisciplinary panel of faculty addressing the impact of social determinants of health on NVAF and CV-related outcomes and strategies to overcome these disparities. In this episode, Laura Ross PA-C, CLS, dives deeper into the impacts of SODH on NVAF care and provides strategies to address to improve patient care and clinical outcomes in NVAF.Review the downloadable slideset and the full program at:    <a href="https://bit.ly/3yYXP8e" rel="nofollow" target="_blank">https://bit.ly/3yYXP8e</a>

Strategies to Overcome SDOH in NVAF

In this episode, Dr. Stanley Cohen, Dr. Sheetal Desai, and Dr. Eric Ruderman discuss the recent changes in rheumatoid arthritis treatment options, reviewing the landscape of targeted DMARDs and JAK inhibitors, including:Kinase signalingJAK inhibitor activity and signalingJAK selectivityPresenters:Stanley B. Cohen, MDClinical Professor Department of Internal MedicineUniversity of Texas Southwestern Medical SchoolCo-DirectorDivision of RheumatologyPresbyterian HospitalCo-Medical DirectorMetroplex Clinical Research CenterDallas, Texas Sheetal Desai, MD, MSEdChief of RheumatologyProgram DirectorUniversity of California, IrvineIrvine, CaliforniaEric M. Ruderman, MDProfessor, Associate ChiefDivision of RheumatologyNorthwestern University Feinberg School of MedicineClinical Practice DirectorNorthwestern Medical GroupChicago, IllinoisDownload the accompanying slides at:https://bit.ly/3447GceSee the interactive video at:https://bit.ly/3oCOtpV

In this episode, Dr. Stanley Cohen, Dr. Sheetal Desai, and Dr. Eric Ruderman discuss the recent changes in rheumatoid arthritis treatment options, reviewing the landscape of targeted DMARDs and JAK inhibitors, including:<ul><li>Kinase signaling</li><li>JAK inhibitor activity and signaling</li><li>JAK selectivity</li></ul>Presenters:Stanley B. Cohen, MD Clinical Professor  Department of Internal Medicine University of Texas Southwestern Medical School Co-Director Division of Rheumatology Presbyterian Hospital Co-Medical Director Metroplex Clinical Research Center Dallas, Texas Sheetal Desai, MD, MSEd Chief of Rheumatology Program Director University of California, Irvine Irvine, CaliforniaEric M. Ruderman, MD Professor, Associate Chief Division of Rheumatology Northwestern University Feinberg School of Medicine Clinical Practice Director Northwestern Medical Group Chicago, IllinoisDownload the accompanying slides at: <a href="https://bit.ly/3447Gce" rel="nofollow" target="_blank">https://bit.ly/3447Gce</a>See the interactive video at: <a href="https://bit.ly/3oCOtpV" rel="nofollow" target="_blank">https://bit.ly/3oCOtpV</a>

A Closer Look at RA Treatment: Targeted DMARDs

In this episode, Dr. Stanley Cohen, Dr. Sheetal Desai, and Dr. Eric Ruderman interpret the latest safety and efficacy data for JAK inhibitors in RA, including the ORAL, BEACON, BEAM, SELECT, and FINCH series inbDMARD-IRMTX-IRMTX naiveAlso included is an in-depth discussion of JAK safety, including MACE and VTE, and use in the clinic including JAK cyclingPresenters:Stanley B. Cohen, MDClinical ProfessorDepartment of Internal MedicineUniversity of Texas Southwestern Medical SchoolCo-DirectorDivision of RheumatologyPresbyterian HospitalCo-Medical DirectorMetroplex Clinical Research CenterDallas, Texas  Sheetal Desai, MD, MSEdChief of RheumatologyProgram DirectorUniversity of California, IrvineIrvine, CaliforniaEric M. Ruderman, MDProfessor, Associate ChiefDivision of RheumatologyNorthwestern University Feinberg School of MedicineClinical Practice DirectorNorthwestern Medical GroupChicago, IllinoisDownload the accompanying slides at:https://bit.ly/37bm6cJSee the interactive video at:https://bit.ly/3oCOtpV

In this episode, Dr. Stanley Cohen, Dr. Sheetal Desai, and Dr. Eric Ruderman interpret the latest safety and efficacy data for JAK inhibitors in RA, including the ORAL, BEACON, BEAM, SELECT, and FINCH series in<ul><li>bDMARD-IR</li><li>MTX-IR</li><li>MTX naive</li></ul>Also included is an in-depth discussion of JAK safety, including MACE and VTE, and use in the clinic including JAK cyclingPresenters:Stanley B. Cohen, MD Clinical Professor Department of Internal Medicine University of Texas Southwestern Medical School Co-Director Division of Rheumatology Presbyterian Hospital Co-Medical Director Metroplex Clinical Research Center Dallas, Texas  Sheetal Desai, MD, MSEd Chief of Rheumatology Program Director University of California, Irvine Irvine, CaliforniaEric M. Ruderman, MD Professor, Associate Chief Division of Rheumatology Northwestern University Feinberg School of Medicine Clinical Practice Director Northwestern Medical Group Chicago, IllinoisDownload the accompanying slides at: <a href="https://bit.ly/37bm6cJ" rel="nofollow" target="_blank">https://bit.ly/37bm6cJ</a>See the interactive video at: <a href="https://bit.ly/3oCOtpV" rel="nofollow" target="_blank">https://bit.ly/3oCOtpV</a>

A Closer Look at RA Treatment: JAK Inhibitor Efficacy and Safety

In this episode, Dr. Stanley Cohen, Dr. Sheetal Desai, and Dr. Eric Ruderman discuss how to translate information on JAK inhibitors and other treatments for your patient population in the clinic, covering practical tips on using:Treat-to-target approachesDisease activity measuresShared decision-makingDecision aidsTranslating clinical trial evidenceAlso included are the experts’ answers to questions from clinicians like you.Stanley B. Cohen, MDClinical ProfessorDepartment of Internal MedicineUniversity of Texas Southwestern Medical SchoolCo-DirectorDivision of RheumatologyPresbyterian HospitalCo-Medical DirectorMetroplex Clinical Research CenterDallas, Texas  Sheetal Desai, MD, MSEdChief of RheumatologyProgram DirectorUniversity of California, IrvineIrvine, CaliforniaEric M. Ruderman, MDProfessor, Associate ChiefDivision of RheumatologyNorthwestern University Feinberg School of MedicineClinical Practice DirectorNorthwestern Medical GroupChicago, IllinoisDownload the accompanying slides at:https://bit.ly/3gHDE3sSee the interactive video at:https://bit.ly/3oCOtpV

In this episode, Dr. Stanley Cohen, Dr. Sheetal Desai, and Dr. Eric Ruderman discuss how to translate information on JAK inhibitors and other treatments for your patient population in the clinic, covering practical tips on using:<ul><li>Treat-to-target approaches</li><li>Disease activity measures</li><li>Shared decision-making</li><li>Decision aids</li><li>Translating clinical trial evidence</li></ul>Also included are the experts’ answers to questions from clinicians like you.Stanley B. Cohen, MD Clinical Professor Department of Internal Medicine University of Texas Southwestern Medical School Co-Director Division of Rheumatology Presbyterian Hospital Co-Medical Director Metroplex Clinical Research Center Dallas, Texas  Sheetal Desai, MD, MSEd Chief of Rheumatology Program Director University of California, Irvine Irvine, CaliforniaEric M. Ruderman, MD Professor, Associate Chief Division of Rheumatology Northwestern University Feinberg School of Medicine Clinical Practice Director Northwestern Medical Group Chicago, IllinoisDownload the accompanying slides at: <a href="https://bit.ly/3gHDE3s" rel="nofollow" target="_blank">https://bit.ly/3gHDE3s</a>See the interactive video at: <a href="https://bit.ly/3oCOtpV" rel="nofollow" target="_blank">https://bit.ly/3oCOtpV</a>

A Closer Look at RA Treatment: Treat-to-Target Using Shared Decision-Making

Weekly updates on new data, current advances, and best practices in patient care for a variety of medical specialties including NASH, diabetes, muscular dystrophy, and more from Clinical Care Options. Gain practical strategies and earn CME/CE credit for selected episodes.

What should our patients with NAFLD eat? Listen as expert hepatologist Rotonya Carr, MD, explores the evidence behind different diets in NAFLD/NASH.Download the slides from this podcast at:https://bit.ly/3gpzuMjSee more NASH topics at:https://bit.ly/3ezkBq6

What should our patients with NAFLD eat? Listen as expert hepatologist Rotonya Carr, MD, explores the evidence behind different diets in NAFLD/NASH.Download the slides from this podcast at: <a href="https://bit.ly/3gpzuMj" rel="nofollow" target="_blank">https://bit.ly/3gpzuMj</a>See more NASH topics at: <a href="https://bit.ly/3ezkBq6" rel="nofollow" target="_blank">https://bit.ly/3ezkBq6</a>

Managing Weight in NAFLD/NASH

Hear Brent A. Neuschwander-Tetri, MD, explore NASH screening and the interplay among NAFLD, metabolic syndrome, CV risk, and diabetes risk, including:Should We Screen for NASH?Role of obesity and type 2 diabetes mellitusCardiovascular Risk in NAFLD/NASHHow to Evaluate for NAFLD/NASHBiomarkersImagingWhen/whom to biopsy?Management in Multidisciplinary SettingsDownload the slides from this podcast at:https://bit.ly/2ZBvVvySee more NASH topics at:https://bit.ly/3ezkBq6

Hear Brent A. Neuschwander-Tetri, MD, explore NASH screening and the interplay among NAFLD, metabolic syndrome, CV risk, and diabetes risk, including:<ul><li>Should We Screen for NASH?<ul><li>Role of obesity and type 2 diabetes mellitus</li></ul></li><li>Cardiovascular Risk in NAFLD/NASH</li><li>How to Evaluate for NAFLD/NASH<ul><li>Biomarkers</li><li>Imaging</li><li>When/whom to biopsy?</li></ul></li><li>Management in Multidisciplinary Settings</li></ul>Download the slides from this podcast at: <a href="https://bit.ly/2ZBvVvy" rel="nofollow" target="_blank">https://bit.ly/2ZBvVvy</a>See more NASH topics at: <a href="https://bit.ly/3ezkBq6" rel="nofollow" target="_blank">https://bit.ly/3ezkBq6</a>

NASH Screening in Diabetes

Hear Stephen A. Harrison, MD, COL (Ret.), FAASLD, weigh the latest perspectives on wet biomarkers, imaging, and combination tests in NASH, including their use in:• Diagnosis of NASH patients with NAS ≥ 4 and fibrosis ≥ F2• Assessment of therapeutic response• Assessment of long-term patient outcomesDownload the slides from this podcast at:https://bit.ly/3il5rqGSee more NASH topics at: https://bit.ly/3ezkBq6

Hear Stephen A. Harrison, MD, COL (Ret.), FAASLD, weigh the latest perspectives on wet biomarkers, imaging, and combination tests in NASH, including their use in: • Diagnosis of NASH patients with NAS ≥ 4 and fibrosis ≥ F2 • Assessment of therapeutic response • Assessment of long-term patient outcomesDownload the slides from this podcast at: <a href="https://bit.ly/3il5rqG" rel="nofollow" target="_blank">https://bit.ly/3il5rqG</a>See more NASH topics at:  <a href="https://bit.ly/3ezkBq6" rel="nofollow" target="_blank">https://bit.ly/3ezkBq6</a>

Noninvasive Tests for NASH

Hear Philip N. Newsome, PhD, FRCPE, discussavailable approaches to managing NASH, including lifestyle, vitamin E, and compounds that target insulin resistance, including:Recommended Pharmacologic Therapies for NASHPioglitazoneVitamin EOptimal Diabetes Therapies in NAFLD/NASHWeight LossLiver HealthSurgical Approaches to Weight Loss and Effect on LiverDownload the slides from this podcast at:https://bit.ly/3ig0r6xSee more NASH topics at:https://bit.ly/3ezkBq6

Hear Philip N. Newsome, PhD, FRCPE, discussavailable approaches to managing NASH, including lifestyle, vitamin E, and compounds that target insulin resistance, including:<ul><li>Recommended Pharmacologic Therapies for NASH<ul><li>Pioglitazone</li><li>Vitamin E</li></ul></li><li>Optimal Diabetes Therapies in NAFLD/NASH<ul><li>Weight Loss</li><li>Liver Health</li></ul></li><li>Surgical Approaches to Weight Loss and Effect on Liver</li></ul>Download the slides from this podcast at:<a href="https://bit.ly/3ig0r6x" rel="nofollow" target="_blank">https://bit.ly/3ig0r6x</a>See more NASH topics at:<a href="https://bit.ly/3ezkBq6" rel="nofollow" target="_blank">https://bit.ly/3ezkBq6</a>

Current NASH Treatments

Hear Dr. Katherine Wagner *and *Dr. Richard Finkle discussnovel gene-based approaches to treating patients with Duchenne muscular dystrophy and limb girdle muscular dystrophies. The latest clinical trial data and gene therapy considerations for product selection including AAV mini-dystrophin and other investigational therapies will be explored.Download the slides from this podcast at: https://bit.ly/2zZgB2XSee more neurology topics at:https://bit.ly/3eAMVby

Hear Dr. Katherine Wagner *and *Dr. Richard Finkle discussnovel gene-based approaches to treating patients with Duchenne muscular dystrophy and limb girdle muscular dystrophies. The latest clinical trial data and gene therapy considerations for product selection including AAV mini-dystrophin and other investigational therapies will be explored.Download the slides from this podcast at:  <a href="https://bit.ly/2zZgB2X" rel="nofollow" target="_blank">https://bit.ly/2zZgB2X</a>See more neurology topics at: <a href="https://bit.ly/3eAMVby" rel="nofollow" target="_blank">https://bit.ly/3eAMVby</a>

New Developments in Gene Therapy for Muscular Dystrophy

Hear Philip N. Newsome, PhD, FRCPE, discuss the agents in late-phase clinical trials and their potential use in the treatment of NASH and fibrosis, including those in phase III such as:Obeticholic acidCenicrivirocResmetiromAramcholDownload the slides from this podcast at:https://bit.ly/3eJYKvWSee more NASH topics at: https://bit.ly/3ezkBq6

Hear Philip N. Newsome, PhD, FRCPE, discuss the agents in late-phase clinical trials and their potential use in the treatment of NASH and fibrosis, including those in phase III such as:<ul><li>Obeticholic acid</li><li>Cenicriviroc</li><li>Resmetirom</li><li>Aramchol</li></ul>Download the slides from this podcast at: <a href="https://bit.ly/3eJYKvW" rel="nofollow" target="_blank">https://bit.ly/3eJYKvW</a>See more NASH topics at:  <a href="https://bit.ly/3ezkBq6" rel="nofollow" target="_blank">https://bit.ly/3ezkBq6</a>

Emerging NASH Treatments

Link to CME: Claim Credit - https://bit.ly/3dQPQwT .Continuous glucose monitoring (CGM) is a great tool that improves clinical outcomes for people with diabetes; these individuals are often happy to get this new technology.However, there can be some initial barriers that both people with diabetes and clinicians need to overcome.BARRIER 1: Wearing something on the body so other people know the person has diabetes.SOLUTION 1: Let the person see the size of different devices through demonstrations and show possible discreet places on the body where they can be worn.Consider starting with a professional CGM, owned by the clinic and borrowed by the individual for up to 14 days, so that he or she can get a feel for what it is like.Consider a CGM that can be integrated with a smart pen instead of an insulin pump, so the individual has only 1 device to wear.BARRIER 2: Cost of the CGM.SOLUTION 2: Find out insurance requirements to see if the CGM can be covered and what is required for coverage.A disposable sensor is a lower cost option. There are coupons available and some pharmacies sell for lower costs.Professional CGM is an underused insurance benefit that is often covered multiple times per year if used on a short- term basis.BARRIER 3: Too much information from CGM can be overwhelming for the individual.SOLUTION 3: Make sure alarms and alerts are set appropriately to avoid alarm fatigue—have the alerts go off when it matters most, like during hypoglycemia. Look at the device at key times only, like before meals, before bedtime, and before activities like exercising and driving, and utilize CGM to determine glycemic trends.BARRIER 4: Clinicians are hesitant to embrace CGM technology.SOLUTION 4: There are various resources available to help clinicians understand CGM technology and to assist in integrating CGM into their practice settings.Online tutorials, industry representatives, and diabetes care and education specialists can help clinicians understand how to start people with diabetes on CGM and how to interpret the data.CPT codes are now available to help support the cost of additional staff to train the individual on the devices and cover the cost of review and interpretation.Presenters:Carla Cox PhD, RD, FAADECertified Diabetes Educator and Clinical DietitianMountain Vista Medicine South Jordan, UtahDiana Isaacs PharmD, BCPS, BCACP, BC-ADM, CDEClinical Pharmacy Specialist/CGM Program CoordinatorDepartment of Endocrinology, Diabetes, and MetabolismCleveland Clinic Diabetes CenterCleveland, OhioProvided by the Endocrine Society in collaboration with the ADCES.Supported by an educational grant from Lilly.

Link to CME: Claim Credit - <a href="https://bit.ly/3dQPQwT" rel="nofollow" target="_blank">https://bit.ly/3dQPQwT</a> .Continuous glucose monitoring (CGM) is a great tool that improves clinical outcomes for people with diabetes; these individuals are often happy to get this new technology.However, there can be some initial barriers that both people with diabetes and clinicians need to overcome.BARRIER 1: Wearing something on the body so other people know the person has diabetes.SOLUTION 1: Let the person see the size of different devices through demonstrations and show possible discreet places on the body where they can be worn.<ul><li>Consider starting with a professional CGM, owned by the clinic and borrowed by the individual for up to 14 days, so that he or she can get a feel for what it is like.</li><li>Consider a CGM that can be integrated with a smart pen instead of an insulin pump, so the individual has only 1 device to wear.</li></ul>BARRIER 2: Cost of the CGM.SOLUTION 2: Find out insurance requirements to see if the CGM can be covered and what is required for coverage.<ul><li>A disposable sensor is a lower cost option. There are coupons available and some pharmacies sell for lower costs.</li><li>Professional CGM is an underused insurance benefit that is often covered multiple times per year if used on a short- term basis.</li></ul>BARRIER 3: Too much information from CGM can be overwhelming for the individual.SOLUTION 3: Make sure alarms and alerts are set appropriately to avoid alarm fatigue—have the alerts go off when it matters most, like during hypoglycemia. Look at the device at key times only, like before meals, before bedtime, and before activities like exercising and driving, and utilize CGM to determine glycemic trends.BARRIER 4: Clinicians are hesitant to embrace CGM technology.SOLUTION 4: There are various resources available to help clinicians understand CGM technology and to assist in integrating CGM into their practice settings.<ul><li>Online tutorials, industry representatives, and diabetes care and education specialists can help clinicians understand how to start people with diabetes on CGM and how to interpret the data.</li><li>CPT codes are now available to help support the cost of additional staff to train the individual on the devices and cover the cost of review and interpretation.</li></ul>Presenters: Carla Cox PhD, RD, FAADE Certified Diabetes Educator and Clinical Dietitian Mountain Vista Medicine  South Jordan, UtahDiana Isaacs PharmD, BCPS, BCACP, BC-ADM, CDE Clinical Pharmacy Specialist/CGM Program Coordinator Department of Endocrinology, Diabetes, and Metabolism Cleveland Clinic Diabetes Center Cleveland, OhioProvided by the Endocrine Society in collaboration with the ADCES. Supported by an educational grant from Lilly.

Role of the Diabetes Care and Education Specialist in CGM

CCO Medical Specialties Podcast

The best podcast episodes on non-current politics. Covering topics such as universal basic income, democracy, poverty & justice and more. For anyone interested in learning more about politics that affect that world, not just now, but in the longer term. Add episodes you're interested into your queue below!

Best Non-Current Politics Podcasts

The best episodes for anyone looking to learn more about topics such as happiness, fulfillment, depression and psychology/mental health in general. With interviews with industry experts, personal stories of individuals, this topic has lessons applicable to everyone. Add episodes you're interested into your queue below!